# Paclitaxel and Cisplatin for Thymic Neoplasm

> **NCT00818090** · PHASE2 · TERMINATED · sponsor: **Korean Cancer Study Group** · enrollment: 39 (actual)

## Conditions studied

- Thymoma
- Thymic Carcinoma

## Interventions

- **DRUG:** paclitaxel and cisplatin

## Key facts

- **NCT ID:** NCT00818090
- **Lead sponsor:** Korean Cancer Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** marginal statistical significance
- **Last updated:** 2013-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00818090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00818090, "Paclitaxel and Cisplatin for Thymic Neoplasm". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00818090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*